(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy...
Stats | |
---|---|
今日成交量 | 2.77M |
平均成交量 | 881 503 |
市值 | 105.77M |
EPS | $-0.0700 ( 2024-02-09 ) |
下一个收益日期 | ( $-0.0600 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.56 |
ATR14 | $0.00200 (0.30%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Mazur Leonard L | Buy | 1 165 048 | Warrant to Purchase Common Stock |
2024-04-03 | Mazur Leonard L | Sell | 1 165 048 | Warrant to Purchase Common Stock |
2024-04-03 | Holubiak Myron Z | Buy | 129 450 | Warrant to Purchase Common Stock |
2024-04-03 | Holubiak Myron Z | Sell | 129 450 | Warrant to Purchase Common Stock |
2024-03-14 | Smith Robert Joseph | Buy | 75 000 | Stock Option (Right to Purchase Common Stock) |
INSIDER POWER |
---|
43.31 |
Last 96 transactions |
Buy: 27 334 255 | Sell: 1 367 765 |
音量 相关性
Citius Pharmaceuticals 相关性 - 货币/商品
Citius Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-194 316 (0.00 %) |
EPS: | $-0.220 |
FY | 2023 |
营收: | $0 |
毛利润: | $-194 316 (0.00 %) |
EPS: | $-0.220 |
FY | 2022 |
营收: | $0 |
毛利润: | $-179 677 (0.00 %) |
EPS: | $-0.230 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.230 |
Financial Reports:
No articles found.
Citius Pharmaceuticals
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。